Doxycycline Hyclate description, usages, side effects, indications, overdosage, supplying and lots more!

Menu
Search

Doxycycline Hyclate

REMEDYREPACK INC.


FULL PRESCRIBING INFORMATION: CONTENTS*




FULL PRESCRIBING INFORMATION

Rx only


DOXYCYCLINE HYCLATE DESCRIPTION


Doxycycline Hyclate

(C22H24N2O8M.W. 1025.89

CLINICAL PHARMACOLOGY






Microbiology


Gram-Negative Bacteria

















Gram-Positive Bacteria






Other Microorganisms

















Susceptibility tests: Diffusion techniques:Quantitative methods that require measurement of zone diameters give the most precise estimate of the susceptibility of bacteria to antimicrobial agents. One such standard procedure1 which has been recommended for use with disks to test susceptibility of organisms to doxycycline uses the 30-mcg tetracycline-class disk or the 30-mcg doxycycline disk. Interpretation involves the correlation of the diameter obtained in the disk test with the minimum inhibitory concentration (MIC) for tetracycline or doxycycline, respectively.

Zone Diameter (mm) Interpretation tetracycline doxycycline

Organism Zone Diameter (mm) tetracycline doxycycline
Dilution techniques:Use a standardized dilution method2 (broth, agar, microdilution) or equivalent with tetracycline powder. The MIC values obtained should be interpreted according to the following criteria:
MIC (mcg/mL) Interpretation
Organism MIC (mcg/mL)

INDICATIONS & USAGE




Treatment:









































Prophylaxis:
DOSAGE AND ADMINISTRATIONsection and Information for Patientssubsection of the PRECAUTIONSsection.)

DOXYCYCLINE HYCLATE CONTRAINDICATIONS


WARNINGS









PRECAUTIONS

General







Information for Patients

















WARNINGS.)

ADVERSE REACTIONS.)

DRUG INTERACTIONS.)

DRUG INTERACTIONS.)





Laboratory Tests



Drug Interactions








Drug/Laboratory Test Interactions


Carcinogenesis, Mutagenesis, Impairment of Fertility






Pregnancy:Teratogenic Effects. Pregnancy Category D:



Nonteratogenic Effects:(See WARNINGS.)

Labor and Delivery


Nursing Mothers
Tetracyclines are excreted in human milk; however, the extent of absorption of tetracyclines, including dpxycycline, by the breastfed infant is not known. Short-term use by lactating women is not necessarilt contraindicated; however, the effects of prolonged exposure to doxycycline in breast milk are unknown. Because of the potential for serious adverse reactions in nursing infants from doxycycline, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. (See
WARNINGS.)

Pediatric Use
WARNINGSand DOSAGE AND ADMINISTRATION.

DOXYCYCLINE HYCLATE ADVERSE REACTIONS


DOSAGE AND ADMINISTRATION.)
WARNINGS.)
WARNINGS.)


PRECAUTIONSGeneral.)

OVERDOSAGE


DOSAGE & ADMINISTRATION






ADVERSE REACTIONS.)













HOW SUPPLIED





STORAGE AND HANDLING





ANIMAL PHARMACOLOGY & OR TOXICOLOGY




REFERENCES

1.National Committee for Clinical Laboratory Standards,Performance Standards for Antimicrobial Disk Susceptibility Tests,Fourth Edition. Approved Standard NCCLS Document M2-A4, Vol. 10,No. 7 NCCLS,Villanova, PA, April 1990.
2.National Committee for Clinical Laboratory Standards,Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically,Second Edition. Approved Standard NCCLS Document M7-A2,Vol. 10,No. 8 NCCLS,Villanova,PA, April 1990.
3.aFriedman JM and Polifka JE. Teratogenic Effects of Drugs. A Resource for Clinicians (TERIS). Baltimore,MD:The Johns Hopkins University Press, 2000:149-195.
cCziezel AE and Rockenbauer M. Teratogenic study of doxycycline. Obstet Gynecol 1997;89:524-528.
cHorne HW Jr and Kundsin RB. The role of mycoplasma among 81 consecutive pregnancies:a prospective study. Int J Fertil 1980;25:315-317.
dHale T. Medications and Mothers Milk. 9th edition. Amarillo, TX: Pharmasoft Publishing,2000:225

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL SECTION














Doxycycline Hyclate


Doxycycline Hyclate

Doxycycline Hyclate

Doxycycline Hyclate CAPSULE

Product Information

Product Type Human prescription drug label Item Code (Source) NDC:52125-135(NDC:53489-119)
Route of Administration ORAL DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength
Doxycycline Hyclate DOXYCYCLINE HYCLATE 100 mg

Inactive Ingredients

Ingredient Name Strength
ANHYDROUS LACTOSE
CROSCARMELLOSE SODIUM
D&C RED NO. 28
FD&C BLUE NO. 1
GELATIN
MAGNESIUM STEARATE
cellulose, microcrystalline
titanium dioxide

Product Characteristics

Color Size Imprint Code Shape
blue 22 mm Mutual;105 CAPSULE

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:52125-135-02 30 in 1 BLISTER PACK

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
ANDA ANDA062676 2012-10-01


PLEASE, BE CAREFUL!
Be sure to consult your doctor before taking any medication!
Copyright © 2014. drugs-library.com. All rights reserved. Information on drugs-library.com is provided for educational purposes only and is not to be used for medical advice, diagnosis or treatment.
Support info@drugs-library.com.